公开(公告)号：EP3690053A1

公开(公告)日：2020-08-05

申请号：EP18862737.6

申请日：2018-09-20

申请人： Green Cross Corporation ,  Mogam Institute for Biomedical Research

发明人： KIM, So Ra ,  JUNG, Myung Eun ,  KIM, Min Jung ,  JO, Seung Hyun ,  HWANG, Sung Ho ,  KWAK, Hee Chun ,  LEE, Su Min ,  NAM, Hyun Ja

IPC分类号： C12N15/85 ,  C12N15/10 ,  C12N15/113 ,  C12N9/22 ,  C12N9/10 ,  C12N9/64 ,  A01K67/027

摘要： The present invention relates to a factor VIII or factor IX gene knockout rabbit, a method for preparing the same and a use thereof and, more particularly, to a transgenic rabbit whose factor VIII or factor IX gene has been knocked out through the CRISPR/Cas9 system, a method for preparing the same and a use thereof. According to the present invention, in the transgenic rabbit, whose factor VIII and/or factor IX gene has been knocked out, the functions of factor VIII and/or factor IX, which are proteins that perform critical functions for the development of hemophilia, are inhibited, such that the transgenic rabbit is useful for the development of hemophilia treatments.

公开(公告)号：EP3476937A1

公开(公告)日：2019-05-01

申请号：EP17815750.9

申请日：2017-06-23

申请人： Mogam Institute for Biomedical Research

发明人： OH, Injae ,  LEE, Seung-Hoon ,  JO, Eui-Cheol ,  OH, Mee Sook ,  RYU, Jae Hwan ,  KIM, Yong Jae ,  KIM, So Ra ,  PARK, Jin-hyun

IPC分类号： C12N9/64 ,  C12N15/62 ,  C07K14/755 ,  A61K38/00

摘要： A chimera protein according to the present application has a significantly increased in vivo half-life when administered because of a vWF domain coupled to FVIII, such that when used as a hemophilia A therapeutic agent, convenience for patients can be increased and medical expenses can be reduced.